STAAR Surgical(US:STAA)2026-03-03 23:32Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the same quarter last year, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [21] - Gross profit margin for Q4 2025 was 75.7%, up from 64.7% in the prior year quarter, primarily due to cost reductions and the ramp-up of Swiss manufacturing [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter [24] Business Line Data and Key Metrics Changes - China net sales in Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [21] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [10] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [11] Company Strategy and Development Direction - The company aims for growth, improving profitability, and progress across its innovation pipeline in 2026, following a challenging 2025 [8] - Focus on enterprise-wide impacts and disciplined investing to drive profitability, including manufacturing improvements and optimizing average selling prices (ASPs) [13] - The launch of EVO+ in China and the expansion of the LIOLI injector for EVO ICL procedures are key components of the growth strategy [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite previous macroeconomic challenges [10] - The company is focused on restoring revenue and maintaining cost discipline, with a target for profitability in FY 2026 [25][26] - Management emphasized the importance of innovation and the need to bring new products to market to maintain competitive advantage [85] Other Important Information - The company has engaged a search firm to find a permanent CEO, indicating a focus on leadership stability during this transition [8] - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] Q&A Session Summary Question: Have the reductions in distributor inventory continued into Q1? - Management confirmed that inventory levels are stable and below contractual levels, indicating readiness for market recovery [32] Question: How does the health of the organization compare to pre-Alcon? - Management noted that expenses have been controlled since Q1 2025, and the organization is aligned around growth and profitability goals [36] Question: What is the expected growth for 2026? - Management refrained from providing specific guidance but expressed optimism about growth in both China and ex-China markets [44] Question: How is the company addressing inventory management in China? - Improved processes and weekly oversight of inventory levels have been implemented to prevent future buildups [47] Question: What is the strategy for U.S. growth versus China growth? - Management emphasized that while China remains the largest opportunity, the U.S. business is also seeing success and will continue to be a focus [53]